Search

Your search keyword '"Neuroendocrine Tumors/classification"' showing total 3 results
Start Over Descriptor "Neuroendocrine Tumors/classification"
3 results on '"Neuroendocrine Tumors/classification"'

1. Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms

Author

Baudin, Eric, Hayes, Aimee R., Scoazec, Jean-Yves, Filosso, Pier Luigi, Lim, Eric, Kaltsas, Gregory, Frilling, Andrea, Chen, Jie, Kos-Kudla, Beata, Gorbunova, Vera, Wiedenmann, Bertram, van Dijkum, Els Nieveen, Cwikla, Jaroslaw B., Falkerby, Jenny, Valle, Juan W., Kulke, Matthew H., Caplin, Martyn E., Detlef, Bartsch, Rudolf, Arnold, Eric, Baudin, Lisa, Bodei, Ivan, Borbath, Jaume, Capdevila, Martyn, Caplin, Jie, Chen, Frederico, Costa, Anne, Couvelard, Jaroslaw, Cwikla B., Philippa, Davies, de Herder, Wouter W., Massimo, Falconi, Jenny, Falkerby, Nicola, Fazio, Diego, Ferone, Andrea, Frilling, Rocio, Garcia-Carbonero, Simona, Glasberg, Vera, Gorbunova, Ashley, Grossman, Dieter, Hoech, Robert, Jensen, Gregory, Kaltsas, Guenter, Kloeppel, Peter, Knigge Ulrich, Beata, Kos-Kudla, Guenter, Krejs J., Eric, Krenning, Matthew, Kulke, Steven, Lamberts W. J., van Elisabeth, Nieveen Dijkum, Juan Manuel, O'Connor, Dermot, O'Toole, Ulrich-Frank, Pape, Stefano, Partelli, Ellen, Pavel Marianne, Peeters, Marc, John, Ramage, Simon, Reed Nicholas, Guido, Rindi, Anja, Rinke, Philippe, Ruszniewski, Halfdan, Sorbye, Anders, Sundin, Jean-Yves, Scoazec, Babs, Taal G., Eva, Tiensuu Janson, Christos, Toumpanakis, Juan, Valle, Marie-Pierre, Vullierme, Staffan, Welin, Bertram, Wiedenmann, ENETS 2016 Munich Advisory Board, Internal Medicine, Baudin, E, Hayes, A R, Scoazec, J-Y, Filosso, Pl, Lim, E, Kaltsas, G, Frilling, A, Chen, J, Kos-Kudla, B, Gorbunova, V, Wiedenmann, B, Nieveen, Van Dijkum E, Cwikla, J B, Falkerby, J, Valle, J W, Kulke, M H, Caplin, M E, on behalf The ENETS 2016 Munich Advisory Board, Participant, Partelli, S, Falconi, M, and Dr. Heinz-Horst Deichmann Stiftung

Subjects
Oncology, Biomedical Research, Lung Neoplasms, SOMATOSTATIN RECEPTORS, Endocrinology, Diabetes and Metabolism, CHROMOGRANIN-A, 030218 nuclear medicine & medical imaging, 0302 clinical medicine, Endocrinology, PROGNOSTIC-FACTORS, PROLIFERATIVE INDEX, Prognosis, Neuroendocrine Tumors, Neuroendocrine Tumors/classification, CUSHINGS-SYNDROME, Tumour classification, ENETS 2016 Munich Advisory Board Participants, Life Sciences & Biomedicine, medicine.medical_specialty, Carcinoid Tumor/classification, 030209 endocrinology & metabolism, Carcinoid Tumor, ENETS CONSENSUS GUIDELINES, 03 medical and health sciences, Cellular and Molecular Neuroscience, Endocrinology & Metabolism, Biomedical Research/trends, Internal medicine, Pulmonary carcinoids, medicine, Humans, EUROPEAN ASSOCIATION, Science & Technology, Endocrine and Autonomic Systems, CLINICAL-FEATURES, Bronchial carcinoid tumour, Neurosciences, 1103 Clinical Sciences, ECTOPIC ACTH SYNDROME, Lung Neoplasms/classification, Clinical trial, NET, Neuroendocrine neoplasm, Bronchial carcinoid tumours, Ectopic ACTH syndrome, Neuroendocrine neoplasms, Neurosciences & Neurology, RECEPTOR RADIONUCLIDE THERAPY, Human medicine, Management principles, Atypical carcinoid, 1109 Neurosciences
Abstract

Pulmonary carcinoids (PCs) display the common features of all well-differentiated neuroendocrine neoplasms (NEN) and are classified as low- and intermediate-grade malignant tumours (i.e., typical and atypical carcinoid, respectively). There is a paucity of randomised studies dedicated to advanced PCs and management principles are drawn from the larger gastroenteropancreatic NEN experience. There is growing evidence that NEN anatomic subgroups have different biology and different responses to treatment and, therefore, should be investigated as separate entities in clinical trials. In this review, we discuss the existing evidence and limitations of tumour classification, diagnostics and staging, prognostication, and treatment in the setting of PC, with focus on unmet medical needs and directions for the future.

Published
2019

2. Colorectal Neuroendocrine Neoplasms

Author

Ramage, John K., Valle, Juan W., van Dijkum, Els J. M. Nieveen, Sundin, Anders, Pascher, Andreas, Couvelard, Anne, Kloeppel, Guenter, Bartsch, Detlef, Arnold, Rudolf, Baudin, Eric, Bodei, Lisa, Borbath, Iva, Capdevila, Jaume, Caplin, Matyn, Chen, Jie, Costa, Frederico, Cwikla, Jaroslaw B., Davies, Philippa, de Herder, Wouter W., Falconi, Massimo, Falkerby, Jenny, Fazio, Nicola, Ferone, Diego, Frilling, Andrea, Garcia-Carbonero, Rocio, Glasberg, Simona, Gorbunova, Vera, Grossman, Ashley, Hoersch, Dieter, Jensen, Robert, Kaltsas, Gregory, Kingge, Ulrich Peter, Kos-Kudla, Beata, Krejs, Guenter J., Krenning, Eric, Kulke, Matthew, Lamberts, Steven W. J., Van Dijkum, Nieveen Els J. M., O'Connor, Juan Manuel, O'Toole, Dermot, Pape, Ulrich-Frank, Partelli, Stefano, Pavel, Marianne Ellen, Peeters, Marc, Reed, Nicholas Simon, Rindi, Guido, Rinke, Anja, Ruszniewski, Philippe, Sorbye, Halfdan, Scoazec, Jean-Yves, Taal, Babs G., Janson, Tiensuu Eva, Toumpanakis, Christos, Vullierme, Marie-Pierre, Staffan, Welin, Wiedenmann, Bertman, ENETS 2016 Munich Advisory Board, Ramage, Jk, Valle, Jw, Nieveen, Van Dijkum EJM, Sundin, A, Pascher, A, Couvelard, A, Kloeppel, G, on behalf of The ENETS 2016 MunichAdvisory Board, Partecipant, Partelli, S, Falconi, M, Internal Medicine, and Radiology & Nuclear Medicine

Subjects
Gastroenteropancreatic neuroendocrine tumour, Oncology, medicine.medical_specialty, Biomedical Research, Colorectal cancer, Endocrinology, Diabetes and Metabolism, Carcinoid tumour, Improved survival, 030209 endocrinology & metabolism, World health, Somatostatin receptor, 030218 nuclear medicine & medical imaging, Unmet needs, 03 medical and health sciences, Cellular and Molecular Neuroscience, Biomedical Research/trends, 0302 clinical medicine, Endocrinology, Internal medicine, Neuroendocrine tumour, Epidemiology, medicine, Colorectal Neoplasms/classification, Humans, Stage (cooking), Endocrine and Autonomic Systems, business.industry, Poorly differentiated, medicine.disease, digestive system diseases, Neuroendocrine Tumors, Neuroendocrine Tumors/classification, Human medicine, business, Colorectal Neoplasms
Abstract

The subject of colorectal neuroendocrine neoplasms (NENs), subdivided into well-differentiated NENs, termed neuroendocrine tumours (NETs; grade (G) 1 and 2), and poorly differentiated NENs, termed neuroendocrine carcinomas (NECs; G3) according to the 2010 World Health Organisation (WHO) classification, has arguably not had as much attention or study as NENs occurring in other sites. Colorectal NETs and NECs are however easier to study than many others since they are usually not difficult to remove and are increasingly detected because of intensified colorectal cancer screening and surveillance programmes. Colorectal NETs and NECs show site-specific heterogeneity with variable behaviour and different therapeutic options; these various aspects provide unique challenges. Because of bowel cancer screening programmes, colorectal NENs, like conventional adenocarcinomas, may be diagnosed at a stage that is associated with improved survival. In this article we intend to describe and define areas of unmet needs relating to the epidemiology, classification, pathology, diagnosis and therapy of colorectal NETs (including NETs G3), colorectal NECs, and finally, mixed adeno-neuroendocrine carcinomas (MANECs) by reviewing and discussing the relevant literature.

Published
2019
Full Text
View/download PDF

3. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal

Author

Günter Klöppel, W. Glenn McCluggage, David S. Klimstra, Manfred Dietel, Behnoush Abedi-Ardekani, Aldo Scarpa, Guido Rindi, Jacqueline Trouillas, Jean-Yves Scoazec, Elisabeth Brambilla, Holger Moch, Hiroko Ohgaki, Klaus J. Busam, Ronald R. de Krijger, William D. Travis, Nicholas S. Reed, Hironobu Sasano, Lynnette Fernandez-Cuesta, Adel K. El-Naggar, Sylvia L. Asa, Frederik T. Bosman, Giovanni Tallini, Ian A. Cree, Brian Rous, Emad A. Rakha, J. Han van Krieken, and Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M, El-Naggar AK, Fernandez-Cuesta L, Klöppel G, McCluggage WG, Moch H, Ohgaki H, Rakha EA, Reed NS, Rous BA, Sasano H, Scarpa A, Scoazec JY, Travis WD, Tallini G, Trouillas J, van Krieken JH, Cree IA

Subjects
0301 basic medicine, medicine.medical_specialty, Pathology, Humans, International Agencies, Neuroendocrine Tumors/classification, World Health Organization, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], Carcinoid tumors, MEDLINE, Neuroendocrine tumors, Mitotic Count, World health, Article, Pathology and Forensic Medicine, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, 0302 clinical medicine, neuroendocrine neoplasms (NENs), medicine, Intensive care medicine, Neuroendocrine neoplasms, classification framework, International Agency for Research on Cancer, World Health Organization, expert consensus, Settore MED/08 - ANATOMIA PATOLOGICA, business.industry, Consensus conference, Expert consensus, NEN, medicine.disease, ddc, Neuroendocrine Tumors, 030104 developmental biology, 030220 oncology & carcinogenesis, business, International agency
Abstract

The classification of neuroendocrine neoplasms (NENs) differs between organ systems and currently causes considerable confusion. A uniform classification framework for NENs at any anatomical location may reduce inconsistencies and contradictions among the various systems currently in use. The classification suggested here is intended to allow pathologists and clinicians to manage their patients with NENs consistently, while acknowledging organ-specific differences in classification criteria, tumor biology, and prognostic factors. The classification suggested is based on a consensus conference held at the International Agency for Research on Cancer (IARC) in November 2017 and subsequent discussion with additional experts. The key feature of the new classification is a distinction between differentiated neuroendocrine tumors (NETs), also designated carcinoid tumors in some systems, and poorly differentiated NECs, as they both share common expression of neuroendocrine markers. This dichotomous morphological subdivision into NETs and NECs is supported by genetic evidence at specific anatomic sites as well as clinical, epidemiologic, histologic, and prognostic differences. In many organ systems, NETs are graded as G1, G2, or G3 based on mitotic count and/or Ki-67 labeling index, and/or the presence of necrosis; NECs are considered high grade by definition. We believe this conceptual approach can form the basis for the next generation of NEN classifications and will allow more consistent taxonomy to understand how neoplasms from different organ systems inter-relate clinically and genetically.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results